Immune checkpoint inhibitors, particularly treatments such as anti-PD-1/PD-L1 and CTLA-4, are effective against a wide range of tumors but have performed poorly in clinical trials in glioma [56]. This evidence concerns the gene CTLA4 and central nervous system cancer.